Enterome
Jean-Marie Carpier is a skilled Research Scientist in Immunology at Enterome since January 2022. Prior to this role, Jean-Marie served as a Postdoctoral Researcher at Yale University School of Medicine from March 2017 to January 2022, focusing on the synergy of DNA damage response modulators with immune checkpoint blockades in cancer therapy under the guidance of a prestigious mentor. Jean-Marie's academic journey includes obtaining a Ph.D. from Institut Curie, where research work from September 2012 to March 2017 revolved around intracellular trafficking in T cell signaling, supervised by Dr. Claire Hivroz. Earlier experience as a Master trainee at Institut Curie involved similar research on T cell signaling and response.
This person is not in any offices
Enterome
Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.